Gnosis By Lesaffre is proud to receive the certification ISO 45001, the international standard for occupational health and safety (OH&S), for the Pisticci Operation Plant.
The company has ever been committed to assure best policy compliance with safety standards.
ISO 45 001 represents the willigness to make Gnosis by Lesaffre a safe place to work and an environment where wellbieng of its collaborators is key.
What is ISO 45 001?
The ISO 45001 has become one of the most eagerly awaited standards in the world, and is set to drastically improve levels of workplace safety. The certification issued to protect employees and visitors from work-related accidents and diseases.
It was developed to mitigate any factors that can cause employees and businesses irreparable harm.
Given that ISO 45001 will become part of the business norm, regardless of whether organizations choose to adopt it or not, it’s important for companies to stay abreast of the latest developments.
DISCOVER ALL OUR LATEST NEWS
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event dedicated to exploring the potential of probiotic yeasts. This live session brought together leading experts to present the latest scientific insights and real-world applications of live yeasts in human health.
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by Lesaffre, led by Jose Pinedo Rivera, Product Manager, had the opportunity to present MyCondro™ to an engaged audience of over 250 industry professionals. The session, titled “Keeping Pace with a Changing World: MyCondro™ Disrupts the Chondroitin Sulfate Market,” was well received, sparking interest and conversations around the future of joint health solutions.
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection, organized by the European Society of Hypertension (ESH), held in Milan in May 23–26, 2025.
